2014

Ceregene Adds Biotech Executive John Walker to Its Board of Directors

    SAN DIEGO, July 12 /PRNewswire-FirstCall/ -- Ceregene, Inc. announced
 today that it has expanded its Board of Directors to 7 members with the
 election of John P. Walker as an independent Board member. Mr. Walker serves
 as an investment advisor to MDS Capital Corp and Executive Chairman of Guava
 Technologies.  He also is vice-chairman of Renovis Inc and a Board member of
 Geron Corp. and several other private companies.
     Mr. Walker brings over 30 years of biotechnology and pharmaceutical
 experience to Ceregene.  His previous experience includes being Chairman and
 CEO of Bayhill Therapeutics; Chairman of Intramed, (now part of Baxter);
 Chairman and Interim CEO of Centaur Pharmaceuticals, (now part of Renovis
 Inc.); Chairman and CEO of AXYS and its predecessor company Arris
 Pharmaceutical, (now part of Celera); Chairman of Signal Pharmaceutical, (now
 part of Celgene); Chairman and CEO of Vitaphore Corporation, (now part of
 Union Carbide); Chairman of Microcide Corporation; and President of The
 Hospital Company of American Hospital Supply Corporation.
     "Ceregene's refined focus on the delivery of nervous system growth factors
 using a gene therapy delivery platform and their accomplishments to date make
 them a very exciting company and I am pleased to join their Board and help
 further their advancement as they continue their clinical trials in
 neurodegenerative disorders," stated John Walker.
     "We believe that Mr. Walker's vast experience in all aspects of biotech
 company development, from start-ups to product licensure and sales, will
 complement our current strong Board of Directors," stated Jeffrey M. Ostrove,
 Ph.D., Ceregene's president and CEO and director.  Mr. Walker will join the
 current Board whose members include its chairman, Stephen A. Sherwin, M.D.,
 chairman and CEO of Cell Genesys, Dennis Henner, Ph.D. of MPM Capital; David
 Mack, Ph.D. of Alta Partners, Eugene Step, past president of the
 pharmaceutical division of Eli Lilly and Mark Tuszynski, M.D., Ph.D.,
 professor of neurosciences, University of California, San Diego.
 
     Ceregene, Inc. is a San Diego-based biotechnology company focused on the
 development of gene therapies for neurodegenerative disorders.  Ceregene is in
 the clinic with CERE-110, an AAV2 based vector expressing nerve growth factor
 that is being tested as a treatment for Alzheimer's disease. CERE-120 for
 Parkinson's disease has regulatory approval and will be tested in the clinic
 shortly and CERE-130 is in late preclinical development for ALS.  Ceregene was
 launched in January 2001 and is a minority-owned subsidiary of Cell Genesys,
 Inc. (Nasdaq:   CEGE), which is headquartered in South San Francisco, CA.
 Ceregene closed a $32M Series B financing in August 2004 that was co-led by
 Alta Partners and MPM Capital.
 
 
     Contact:  Jeffrey M. Ostrove, Ph.D.
               President and Chief Executive Officer
               Ceregene, Inc.
               858-458-8808
 
 

SOURCE Ceregene, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.